Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.86
ALIOF's Cash to Debt is ranked lower than
69% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ALIOF: 2.86 )
Ranked among companies with meaningful Cash to Debt only.
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7  Med: 4.14 Max: N/A
Current: 2.86
Equity to Asset 0.62
ALIOF's Equity to Asset is ranked lower than
59% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALIOF: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.58 Max: 0.72
Current: 0.62
0.5
0.72
Interest Coverage 58.07
ALIOF's Interest Coverage is ranked lower than
85% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 58.07 )
Ranked among companies with meaningful Interest Coverage only.
ALIOF' s 10-Year Interest Coverage Range
Min: 0.3  Med: 58.07 Max: 9999.99
Current: 58.07
0.3
9999.99
F-Score: 6
Z-Score: 14.65
M-Score: -2.97
WACC vs ROIC
2.31%
48.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.77
ALIOF's Operating margin (%) is ranked higher than
91% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ALIOF: 28.77 )
Ranked among companies with meaningful Operating margin (%) only.
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68  Med: 23.70 Max: 29.11
Current: 28.77
0.68
29.11
Net-margin (%) 23.41
ALIOF's Net-margin (%) is ranked higher than
89% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ALIOF: 23.41 )
Ranked among companies with meaningful Net-margin (%) only.
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15  Med: 18.92 Max: 30.33
Current: 23.41
-8.15
30.33
ROE (%) 25.49
ALIOF's ROE (%) is ranked higher than
94% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ALIOF: 25.49 )
Ranked among companies with meaningful ROE (%) only.
ALIOF' s 10-Year ROE (%) Range
Min: -9.03  Med: 28.58 Max: 55.02
Current: 25.49
-9.03
55.02
ROA (%) 17.75
ALIOF's ROA (%) is ranked higher than
94% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ALIOF: 17.75 )
Ranked among companies with meaningful ROA (%) only.
ALIOF' s 10-Year ROA (%) Range
Min: -5.28  Med: 15.22 Max: 21.54
Current: 17.75
-5.28
21.54
ROC (Joel Greenblatt) (%) 106.38
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ALIOF: 106.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5.65  Med: 90.40 Max: 161.39
Current: 106.38
-5.65
161.39
Revenue Growth (3Y)(%) 2.20
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
55% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALIOF: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALIOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.4  Med: 3.25 Max: 28.2
Current: 2.2
-22.4
28.2
EBITDA Growth (3Y)(%) 128.40
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ALIOF: 128.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45  Med: 7.60 Max: 128.4
Current: 128.4
-45
128.4
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.40
ALIOF's P/E(ttm) is ranked lower than
54% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. ALIOF: 49.40 )
Ranked among companies with meaningful P/E(ttm) only.
ALIOF' s 10-Year P/E(ttm) Range
Min: 19.12  Med: 21.42 Max: 50.97
Current: 49.4
19.12
50.97
Forward P/E 37.74
ALIOF's Forward P/E is ranked lower than
71% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. ALIOF: 37.74 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 49.20
ALIOF's PE(NRI) is ranked lower than
56% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ALIOF: 49.20 )
Ranked among companies with meaningful PE(NRI) only.
ALIOF' s 10-Year PE(NRI) Range
Min: 19.26  Med: 21.57 Max: 50.84
Current: 49.2
19.26
50.84
P/B 11.46
ALIOF's P/B is ranked lower than
82% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ALIOF: 11.46 )
Ranked among companies with meaningful P/B only.
ALIOF' s 10-Year P/B Range
Min: 6.09  Med: 6.84 Max: 11.84
Current: 11.46
6.09
11.84
P/S 8.24
ALIOF's P/S is ranked higher than
58% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ALIOF: 8.24 )
Ranked among companies with meaningful P/S only.
ALIOF' s 10-Year P/S Range
Min: 5.91  Med: 6.63 Max: 8.45
Current: 8.24
5.91
8.45
PFCF 26.55
ALIOF's PFCF is ranked higher than
67% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. ALIOF: 26.55 )
Ranked among companies with meaningful PFCF only.
ALIOF' s 10-Year PFCF Range
Min: 21.13  Med: 26.84 Max: 127.71
Current: 26.55
21.13
127.71
POCF 25.27
ALIOF's POCF is ranked higher than
63% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. ALIOF: 25.27 )
Ranked among companies with meaningful POCF only.
ALIOF' s 10-Year POCF Range
Min: 20.09  Med: 25.55 Max: 95.78
Current: 25.27
20.09
95.78
EV-to-EBIT 27.55
ALIOF's EV-to-EBIT is ranked higher than
53% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ALIOF: 27.55 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s 10-Year EV-to-EBIT Range
Min: 18.5  Med: 20.90 Max: 27.7
Current: 27.55
18.5
27.7
PEG 3.00
ALIOF's PEG is ranked lower than
52% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.73 vs. ALIOF: 3.00 )
Ranked among companies with meaningful PEG only.
ALIOF' s 10-Year PEG Range
Min: 0  Med: 0.00 Max: 0
Current: 3
Shiller P/E 50.34
ALIOF's Shiller P/E is ranked lower than
53% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.33 vs. ALIOF: 50.34 )
Ranked among companies with meaningful Shiller P/E only.
ALIOF' s 10-Year Shiller P/E Range
Min: 38.57  Med: 41.78 Max: 50.34
Current: 50.34
38.57
50.34
Current Ratio 1.80
ALIOF's Current Ratio is ranked lower than
76% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALIOF: 1.80 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s 10-Year Current Ratio Range
Min: 1.75  Med: 2.35 Max: 3.95
Current: 1.8
1.75
3.95
Quick Ratio 1.72
ALIOF's Quick Ratio is ranked lower than
73% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ALIOF: 1.72 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7  Med: 2.28 Max: 3.8
Current: 1.72
1.7
3.8
Days Inventory 109.13
ALIOF's Days Inventory is ranked higher than
55% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. ALIOF: 109.13 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s 10-Year Days Inventory Range
Min: 87.04  Med: 101.82 Max: 129.97
Current: 109.13
87.04
129.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.98
ALIOF's Dividend Yield is ranked lower than
56% of the 218 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALIOF: 0.98 )
Ranked among companies with meaningful Dividend Yield only.
ALIOF' s 10-Year Dividend Yield Range
Min: 0.9  Med: 1.57 Max: 2.7
Current: 0.98
0.9
2.7
Dividend Payout 0.33
ALIOF's Dividend Payout is ranked higher than
62% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.37 vs. ALIOF: 0.33 )
Ranked among companies with meaningful Dividend Payout only.
ALIOF' s 10-Year Dividend Payout Range
Min: 0  Med: 0.00 Max: 0
Current: 0.33
Yield on cost (5-Year) 0.98
ALIOF's Yield on cost (5-Year) is ranked lower than
63% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.42 vs. ALIOF: 0.98 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.9  Med: 1.57 Max: 2.7
Current: 0.98
0.9
2.7
Share Buyback Rate 0.70
ALIOF's Share Buyback Rate is ranked higher than
95% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. ALIOF: 0.70 )
Ranked among companies with meaningful Share Buyback Rate only.
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7  Med: 0.80 Max: -81.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 3.60
ALIOF's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ALIOF: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALIOF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.6  Med: 4.80 Max: 5.4
Current: 3.6
3.6
5.4

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1,725 1,718 1,770
EPS($) 2.85 3.14 2.43
EPS without NRI($) 2.85 3.14 2.43

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK,
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Lexicon Pharmaceuticals (LXRX) in Focus: Stock Rises 61.1% - Tale of the Tape Aug 04 2015
Integra Tops Earnings & Revenues, Guides Low on Spine Sale - Analyst Blog Aug 03 2015
OncoMed Pharmaceuticals (OMED) Jumps: Stock Rises 5.4% - Tale of the Tape Aug 03 2015
Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog Jul 31 2015
Qiagen (QGEN) Beats Q2 Earnings, Revenues; Keeps '15 View - Analyst Blog Jul 31 2015
AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog Jul 31 2015
Vanda Pharmaceuticals (VNDA) Jumps: Stock Moves Up 8.4% - Tale of the Tape Jul 31 2015
The Medicines Co. Down on Wider-than-Expected Loss in Q2 - Analyst Blog Jul 30 2015
Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog Jul 30 2015
New Strong Buy Stocks for July 24th - Tale of the Tape Jul 24 2015
Idera Pharmaceuticals (IDRA) in Focus: Stock Jumps 5.3% - Tale of the Tape Jul 24 2015
Actelion Misses on Q2 Earnings, Revenues Beat Expectations - Analyst Blog Jul 22 2015
Actelion delivers excellent first half 2015 results Jul 21 2015
Actelion to discuss first half 2015 financial results Jul 16 2015
Actelion creates Vaxxilon together with the Max Planck Society Jun 26 2015
New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects... Jun 25 2015
Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog Jun 22 2015
Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog Jun 22 2015
Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog Jun 22 2015
Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape Jun 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK